Revolade(Eltrombopag) Instructions:Uses,Dosage, Side Effects

Treatment of thrombocytopenia in adults and pediatric patients (≥1 year) with persistent or chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Treatment of thrombocytopenia in patients with chronic hepatitis C to enable initiation and maintenance of interferon-based therapy.

First-line treatment of severe aplastic anemia in combination with immunosuppressive therapy (IST) in adults and pediatric patients (≥2 years).

Treatment of severe aplastic anemia in patients with an insufficient response to immunosuppressive therapy.

Administer orally once daily on an empty stomach or with a low-calcium meal (≤50 mg calcium). Avoid concurrent use with polyvalent cation-containing products (e.g., antacids, dairy) within 2 hours before or 4 hours after dosing.

Dosing is individualized based on indication, age, hepatic function, and ethnicity (e.g., reduced initial doses for East/Southeast Asian patients or those with hepatic impairment).

Monitor platelet counts regularly and adjust dose to achieve target platelet levels (e.g., ≥50×10⁹/L for ITP). Maximum daily doses: 75 mg (ITP), 100 mg (hepatitis C), 150 mg (SAA).

Oral suspension must be reconstituted with water and administered immediately (within 30 minutes).